Anika Therapeutics Q3 net loss narrows 87% to $311,000; Q3 revenue rises 10% to $30.59 million
Bitget2026/11/06 12:07- Anika Therapeutics’ third-quarter 2026 net loss narrowed 87% year over year to $311,000.
- Revenue rose 10% year over year to $30.59 million, while Commercial Channel revenue climbed 17% to $13.99 million.
- The FDA deemed the Hyalofast premarket approval application not approvable, primarily based on submitted clinical data.
- A new 10-year Hyvisc distribution partnership with Boehringer Ingelheim includes $8 million in expected upfront and milestone payments.
- Full-year 2026 revenue growth guidance increased to 6%–10% from 5%–10%.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
British Pound hits session highs at 1.3420 amid broadbased US Dollar weakness
Cybertruck orders far exceed pre-production capacity, Tesla (TSLA.US) to refund deposits to a large number of customers
Elon Musk stated that Tesla will refund the Cybertruck deposits to a significant number of customers.
Barrick Gold (B.US) Q3 Results Mixed: Benefiting from Gold Price Dividend While Facing Cost Pressures
Barrick Mining (B.US) will release its financial results for the third quarter of 2026 before the U.S. stock market opens on November 9.
Crypto prices
More
